23andMe

23andMe
23andMe · Public domain · source
Name	23andMe
Type	Private
Founded	2006
Founders	Anne Wojcicki; Linda Avey; Paul Cusenza
Headquarters	Mountain View, California
Products	Direct-to-consumer genetic testing, Health reports, Ancestry reports, Research services

23andMe 23andMe is a consumer genetics and biotechnology company providing direct-to-consumer DNA testing and genetic reports. Founded in 2006 during the era of expanding genomics companies, the company operates at the intersection of personal genomics, biomedical research, and digital platforms. It has influenced debates involving health data, biotechnology startups, and regulatory agencies across the United States and Europe.

History

The company was founded in 2006 by Anne Wojcicki, Linda Avey, and Paul Cusenza amid broader entrepreneurial activity alongside Google, Apple Inc., Facebook, Illumina, and 23andMe rival companies during a period of private financing led by investors such as Genentech, Khosla Ventures, and Third Rock Ventures. Early milestones included launching consumer kits and media coverage in outlets like The New York Times, Wall Street Journal, and Wired (magazine), while navigating industry events such as the growth of Personalized medicine initiatives and collaborations with academic centers like Stanford University, University of California, San Francisco, and Harvard Medical School. The company expanded internationally into markets including the United Kingdom, Canada, and Australia and attracted strategic partnerships with firms such as GlaxoSmithKline, Pfizer, and Johnson & Johnson amid discussions involving FDA oversight and regulatory scrutiny from agencies including European Medicines Agency and UK Medicines and Healthcare products Regulatory Agency. Leadership changes, fundraising rounds, and litigation with entities like Ancestry.com and privacy advocates shaped its corporate trajectory alongside cultural moments involving public figures and celebrities who used consumer genetics, including mentions in profiles of entrepreneurs like Sergey Brin, Mark Zuckerberg, and Elon Musk.

Services and products

The company offers consumer-facing saliva-based genotyping kits with ancestry composition results, health predisposition reports, carrier status reports, and traits information, competing with firms such as Ancestry.com, MyHeritage, FamilyTreeDNA, Helix (company), and Color Genomics. Services include ancestry composition, maternal and paternal haplogroup assignments, and relative-matching features used by customers and genealogists associated with organizations like National Genealogical Society, Library of Congress, and Smithsonian Institution. Health and wellness reports have covered conditions linked to loci studied in consortia such as International HapMap Project, 1000 Genomes Project, and UK Biobank, while research initiatives have connected customer-consented data with pharmaceutical programs at GlaxoSmithKline, Pfizer, and academic studies at Broad Institute, Massachusetts General Hospital, and Columbia University.

Technology and methodology

The company uses genotyping arrays based on single nucleotide polymorphism (SNP) microarray platforms developed by manufacturers like Illumina and algorithms informed by reference panels from projects such as 1000 Genomes Project, HapMap Project, and Human Genome Project. Bioinformatics processing pipelines integrate ancestry deconvolution methods similar to approaches used at Broad Institute, Wellcome Sanger Institute, and European Bioinformatics Institute and apply imputation and phasing strategies paralleling tools from PLINK (software), SHAPEIT, and IMPUTE. Quality control, laboratory workflows, and sample tracking adhere to standards referenced by institutions including College of American Pathologists, Clinical Laboratory Improvement Amendments, and regulatory guidance from Food and Drug Administration and European Commission research directives.

Privacy, data security, and ethics

Privacy practices, data sharing policies, and informed consent frameworks have been shaped by debates involving Federal Trade Commission, Office for Civil Rights (OCR), advocacy groups such as Electronic Frontier Foundation, ACLU, and Genetic Alliance, and academic bioethics centers at Johns Hopkins University, Yale University, and University of Oxford. Ethical questions have focused on law enforcement access highlighted by cases involving Golden State Killer investigations and policy discussions involving Department of Justice, FBI, and state-level legislatures including the California State Legislature. Data security measures reference standards from National Institute of Standards and Technology, ISO/IEC, and corporate agreements with partners like GlaxoSmithKline and Pfizer that raised scrutiny from privacy regulators such as Information Commissioner's Office in the United Kingdom.

Business model and partnerships

The company’s revenue streams include direct-to-consumer kit sales, subscription services, and research collaborations with pharmaceutical firms and academic consortia such as GlaxoSmithKline, Pfizer, Broad Institute, Harvard Medical School, and University of California system. Strategic alliances and licensing deals have been reported in negotiations reminiscent of partnerships between Genentech and Roche, or startup collaborations with Merck and Novartis, while investor relationships include venture capital firms such as Khosla Ventures, Founders Fund, and private equity participants. The company has pursued secondary markets, data licensing, and therapeutic discovery programs that mirror business developments seen at 23andMe competitors and biotechnology ventures incubated near Silicon Valley and Boston (massachusetts) biotech clusters.

Regulatory and legal issues

Regulatory interactions include orders, clearances, and communications with the Food and Drug Administration concerning health-related reports, enforcement actions paralleling other direct-to-consumer health companies like Theranos, and litigation involving intellectual property disputes similar to cases heard in United States District Court for the Northern District of California and arbitration settings invoking laws like the Health Insurance Portability and Accountability Act of 1996 and consumer protection statutes enforced by the Federal Trade Commission. International regulatory environments involved consultations with European Medicines Agency, UK Medicines and Healthcare products Regulatory Agency, and national data protection authorities such as the Information Commissioner's Office.

Reception and impact

The company has received mixed reception among scientific communities at American Society of Human Genetics, public health authorities at Centers for Disease Control and Prevention, and patient advocacy organizations including National Institutes of Health-affiliated programs and nonprofits like Alzheimer's Association and American Cancer Society. News coverage in outlets such as The New York Times, The Guardian, and The Washington Post framed debates about consumer access to health information, while scholarly critiques from journals connected to Nature, Science (journal), and The Lancet examined validity and utility. Its influence extends into genealogy communities affiliated with Ancestry.com, legal policy dialogues with Department of Justice, and commercial biotech sectors in Silicon Valley and Cambridge, Massachusetts.

Category:Biotechnology companies